uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Radiology.
2016 (English)In: Acta Neurologica Scandinavica, ISSN 0001-6314, E-ISSN 1600-0404, Vol. 133, no 3, 208-215 p.Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To evaluate the safety and tolerability of the T-Port(®) for intestinal infusion of levodopa/carbidopa gel in patients with advanced Parkinson's disease (PD).

METHODS: This prospective study was carried out in 24 patients with PD (15 males, mean age 61.8 years, mean duration PD 18.7 years). All adverse device effects were evaluated at 2 weeks, 3 months and 6 months and until explantation or death.

RESULTS: Post-operative complications were similar to endoscopic gastrojejunostomy placement (four peritoneal irritation, one pocket pain). Eight patients with prior experience with the endoscopic gastrojejunostomy preferred the T-Port. The total device experience was 83.6 years, and the average survival time was 3.6 (range 1.1-5.2) years. Six T-Ports were still in use, and two patients had died due to non-device-related reasons. Sixteen T-Ports had been explanted due to 15 stoma reactions (14 inflammations and one infection) and one tilting of the T-Port. The T-Ports were replaced with endoscopic gastrojejunostomy system as replacements with T-Ports were not part of the study. Only two device malfunctions occurred (one catheter breakage at 3 year post-implant and one T-Port leakage of levodopa/carbidopa gel). No tube kinking, dislocation or blockage occurred. The number of adverse device effects proved to be significantly lower as compared to the endoscopic gastrojejunostomy literature data.

CONCLUSIONS: The T-Port is safe and well tolerated, and the low number of tube problems is a potential advantage compared with the endoscopic gastrojejunostomy system. Proper cleaning and local treatment of the stoma site around the T-Port are essential to prolong its longevity.

Place, publisher, year, edition, pages
2016. Vol. 133, no 3, 208-215 p.
Keyword [en]
clinical trial; levodopa/carbidopa infusion; Parkinson's disease; percutaneous endoscopic gastrojejunostomy; transcutaneous port
National Category
URN: urn:nbn:se:uu:diva-261204DOI: 10.1111/ane.12464ISI: 000371628100006PubMedID: 26213103OAI: oai:DiVA.org:uu-261204DiVA: diva2:850037
Swedish Research CouncilVINNOVA
Available from: 2015-08-31 Created: 2015-08-31 Last updated: 2016-04-14Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Nyholm, DagNyman, Rickard
By organisation
In the same journal
Acta Neurologica Scandinavica

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 384 hits
ReferencesLink to record
Permanent link

Direct link